Literature DB >> 20035387

Treatment of newly diagnosed multiple myeloma: advances in current therapy.

Shaji Kumar1.   

Abstract

The past decade has seen incredible progress in the treatment of myeloma as a result of more widespread application of autologous stem cell transplantation and introduction of several new drugs. Hence, the survival of patients with this disease has significantly improved during this period. The treatment approach for patients with myeloma has undergone a paradigm shift as a result of the different choices available for treating the patients with newly diagnosed myeloma. In addition, appreciation of the heterogeneity in the outcome of these patients and the impact of genetics on the prognosis has led to efforts at developing a risk-adapted approach to treatment. This article summarizes the recent advances in the treatment of newly diagnosed myeloma and suggests a treatment algorithm for approaching newly diagnosed myeloma.

Entities:  

Mesh：

Year:  2009        PMID： 20035387     DOI： 10.1007/s12032-009-9370-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  51 in total

1.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  S Vincent Rajkumar; Emily Blood; David Vesole; Rafael Fonseca; Philip R Greipp
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

2.  High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

Authors:  Jean-Paul Fermand; Sandrine Katsahian; Marine Divine; Veronique Leblond; Francois Dreyfus; Margaret Macro; Bertrand Arnulf; Bruno Royer; Xavier Mariette; Edouard Pertuiset; Coralie Belanger; Maud Janvier; Sylvie Chevret; Jean Claude Brouet; Philippe Ravaud
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

3.  Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

Authors:  Sundar Jagannath; Brian G M Durie; Jeffrey Wolf; Elber Camacho; David Irwin; Jose Lutzky; Marti McKinley; Eli Gabayan; Amitabha Mazumder; David Schenkein; John Crowley
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

Review 5.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Authors:  Martha Q Lacy; Angela Dispenzieri; Morie A Gertz; Philip R Greipp; Kimberly L Gollbach; Suzanne R Hayman; Shaji Kumar; John A Lust; S Vincent Rajkumar; Stephen J Russell; Thomas E Witzig; Steven R Zeldenrust; David Dingli; P Lief Bergsagel; Rafael Fonseca; Craig B Reeder; A Keith Stewart; Vivek Roy; Robert J Dalton; Alan B Carr; Deepak Kademani; Eugene E Keller; Christopher F Viozzi; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

6.  A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.

Authors:  A K Stewart; P L Bergsagel; P R Greipp; A Dispenzieri; M A Gertz; S R Hayman; S Kumar; M Q Lacy; J A Lust; S J Russell; T E Witzig; S R Zeldenrust; D Dingli; C B Reeder; V Roy; R A Kyle; S V Rajkumar; R Fonseca
Journal:  Leukemia       Date:  2007-01-18       Impact factor: 11.528

7.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.

Authors:  Antonio Palumbo; Sara Bringhen; Maria Teresa Petrucci; Pellegrino Musto; Fausto Rossini; Martina Nunzi; Vito Michele Lauta; Cesare Bergonzi; Anna Barbui; Tommaso Caravita; Antonio Capaldi; Patrizia Pregno; Tommasina Guglielmelli; Mariella Grasso; Vincenzo Callea; Alessandra Bertola; Federica Cavallo; Patrizia Falco; Cecilia Rus; Massimo Massaia; Franco Mandelli; Angelo Michele Carella; Enrico Pogliani; Anna Marina Liberati; Franco Dammacco; Giovannino Ciccone; Mario Boccadoro
Journal:  Blood       Date:  2004-07-20       Impact factor: 22.113

Review 9.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

Review 10.  Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.

Authors:  E Alyea; E Weller; R Schlossman; C Canning; P Mauch; A Ng; D Fisher; J Gribben; A Freeman; B Parikh; P Richardson; R Soiffer; J Ritz; K C Anderson
Journal:  Bone Marrow Transplant       Date:  2003-12       Impact factor: 5.483
View more
  3 in total

1.  Referrals for suspected hematologic malignancy: a survey of primary care physicians.

Authors:  Gregory A Abel; Christopher R Friese; Bridget A Neville; Katherine M Wilson; B Taylor Hastings; Craig C Earle; Nancy L Keating; Lisa C Richardson
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

2.  BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.

Authors:  Ye Yang; Chunyan Gu; Chen Luo; Fei Li; Min Wang
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

3.  Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

Authors:  Shaji K Kumar; Betsy LaPlant; Wee Joo Chng; Jeffrey Zonder; Natalie Callander; Rafael Fonseca; Briant Fruth; Vivek Roy; Charles Erlichman; A Keith Stewart
Journal:  Blood       Date:  2014-11-13       Impact factor: 25.476
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.